Latest news with #Peptide-1
Hindustan Times
23-04-2025
- Health
- Hindustan Times
Weight loss at the cost of mental health? Study reveals Ozempic increases depression risk
Ozempic is a hot topic, with constant buzz around its ability to suppress appetite and aid in weight loss, leading some Hollywood celebrities to adopt this diabetes drug. While many have applauded its effectiveness, others have raised alarms about its potential physical side effects, like nausea and vomiting. A study published in Current Neuropharmacology revealed a crucial side effect: Ozempic impairs mental wellbeing. Ozempic may negatively affect mental health, increasing the risk of depression and suicidal thoughts, per the findings of the study. ALSO READ: What is 'Ozempic feet'? THESE celebs may be exhibiting weight-loss drug's shocking side effect As per the study, it turns out that the Glucagon-like Peptide-1, the GLP-1 receptor agonists, the active components present in drugs like Ozempic could influence the dopamine system. For good mood, dopamine is one of the vital hormones. With dopamine disrupted, feelings of sadness, low motivation and even suicidal thoughts become prominent. Moreover, the low mood affects the quality of life, hindering daily functioning and routine. However, the depression risk is not applicable to everyone, as genes are the reason. The study elaborated further that people who are genetically predisposed to lower natural dopamine levels are more likely to experience depression after using Ozempic. The researchers analysed and found that GLP-1 drugs, like Ozempic, target certain genes like DRD3, BDNF, and CREB1. This can further worsen depressive symptoms. While there's no advocacy for a complete ban in the study, the study urged people to proceed with caution, understanding the risks. Before prescribing Ozempic, a thorough check of an individual's genetic background should be considered. These risk factors could help determine whether Ozempic should be prescribed or not. The study didn't deny the weight loss benefits but instead emphasised the need for precaution. Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition. ALSO READ: Extra virgin olive oil is 'better than Ozempic'? Here's what anti-ageing millionaire Bryan Johnson said
Globe and Mail
03-04-2025
- Business
- Globe and Mail
Glucagon-Like Peptide-1 Agonists Market Poised for Substantial Growth Through 2034
The key Glucagon-Like Peptide-1 Agonists companies in the market include - AstraZeneca, Pfizer, Boehringer Ingelheim, Eli Lilly and Company, and Novo Nordisk, among others. The latest comprehensive report by DelveInsight delivers detailed insights into the current and forecasted GLP-1 market size across 7MM, covering the period from 2020 to 2034. The glucagon market has witnessed transformative growth in recent years as GLP-1 agonists continue to demonstrate exceptional efficacy in managing type 2 diabetes and weight-related conditions. Key GLP-1 companies driving the growth in this landscape include AstraZeneca, Pfizer, Boehringer Ingelheim, Eli Lilly and Company, and Novo Nordisk, among others. According to DelveInsight's latest report, ' Glucagon-like Peptide-1 (GLP-1) Agonists Market Size, Target Population, Competitive Landscape & Market Forecast ', the Glucagon-like Peptide-1 (GLP-1) agonists market is projected to expand at a significant CAGR through 2034. The GLP-1 therapeutics market is primarily driven by the rising global diabetes epidemic, with approximately 537 million adults living with diabetes as of 2021. Type 2 diabetes mellitus accounts for over 85% of all diabetes cases, with about 1.4 million new cases diagnosed in the United States alone each year. The condition disproportionately affects older adults, with prevalence exceeding 25% among those over 65 years of age. The GLP-1 epidemiology landscape continues to evolve as researchers gain deeper insights into the prevalence and distribution of type 2 diabetes and obesity across different demographic groups. DelveInsight's analysis indicates a substantial eligible patient population for GLP-1 therapy, with both diabetes and obesity rates projected to increase throughout the forecast period, further driving demand for effective therapeutic interventions. Learn more about GLP-1 agonists patient trends by leveraging DelveInsight's expert analysis on GLP-1 epidemiological data The report also discusses the Glucagon-like Peptide-1 agonists treatment landscape which encompasses various administration options, including injectable and oral formulations, providing patients and healthcare providers with flexible therapeutic approaches. The current GLP-1 drug market is dominated by several key players and their approved medications. Regulatory bodies have approved multiple GLP-1 receptor agonists, including TRULICITY (Eli Lilly), BYETTA/BYDUREON (AstraZeneca), VICTOZA (Novo Nordisk), OZEMPIC/WEGOVY (Novo Nordisk), and MOUNJARO/ZEPBOUND (Eli Lilly and Company), among others. These medications have demonstrated efficacy in glycemic control and, in some cases, significant weight management benefits, further solidifying their position in the treatment paradigm for metabolic disorders. The GLP-1 pipeline shows promising results, with several innovative candidates advancing through clinical development. Some of the therapies include orforglipron (Eli Lilly and Company), survodutide (Boehringer Ingelheim), danuglipron (Pfizer), and retatrutide (Eli Lilly and Company), among others. These emerging therapies aim to address current treatment gaps, improve efficacy profiles, and reduce side effects, potentially reshaping the competitive landscape in the coming years. To uncover key insights into the rapidly growing GLP-1 agonists competitive dynamics and emerging innovations, visit the GLP-1 Market Insights Recent developments highlight the expanding applications of GLP-1 agonists beyond traditional diabetes management. In July 2024, a significant milestone was reached when the MHRA approved semaglutide to reduce the risk of serious heart problems in obese or overweight adults, making it the first weight-loss drug approved in the UK as a preventative treatment for cardiovascular disease. Additionally, Roche announced promising early weight loss results from Phase I trials of its oral GLP-1 receptor agonist in July 2024. Further, in November 2024, the FDA approved a generic version of BYETTA (AstraZeneca) by Amneal Pharmaceuticals. This was followed by the approval of a generic version of another GLP-1 receptor agonist, VICTOZA (Novo Nordisk), in December 2024, manufactured by Hikma Pharmaceuticals, suggesting a growing demand in the GLP-1 agonists landscape. In conclusion, the Glucagon-like Peptide-1 agonists market is poised for significant growth through 2034, driven by the increasing prevalence of type 2 diabetes and obesity worldwide. With a robust pipeline of innovative therapies from leading pharmaceutical companies, the market is expected to witness transformative changes in treatment paradigms. As new formulations and delivery methods emerge, patient outcomes are likely to improve, potentially expanding the applications of GLP-1 agonists beyond diabetes management. However, challenges such as pricing, reimbursement, and market access will continue to shape the competitive landscape. Stakeholders in the healthcare industry should closely monitor these developments to capitalize on the expanding opportunities in the GLP-1 therapeutics market. Table of Contents 1. Key Insights 2. Report Introduction 3. Executive Summary of GLP-1 Agonists 4. Key Events 5. GLP-1 Agonists Market Overview At A Glance 6. Background And Overview 7. Target Population 8. GLP-1 Agonists Marketed Drugs 9. GLP-1 Agonists Emerging Drugs 10. GLP-1 Agonists: The 7MM Analysis 11. GLP-1 Agonists Unmet Needs 12. SWOT Analysis 13. KOL Views 14. GLP-1 Agonists Market Access and Reimbursement 15. Appendix 16. Delveinsight Capabilities 17. Disclaimer 18. About DelveInsight Related Reports Diabetes Pipeline Insight Diabetes Pipeline Insight provides comprehensive insights about the Diabetes pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Diabetes companies, including vTv Therapeutics (VTVT), Tonghua Dongbao Pharmaceutical, Eli Lilly and Company (LLY), Celon Pharma (CLN), Sciwind Biosciences, AstraZeneca (AZN), Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, and Chong Kun Dang Pharmaceutical among others. About DelveInsight DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence. Media Contact Company Name: DelveInsight Contact Person: Arpit Anand Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
